Upregulation of interleukin-19 in severe asthma: a potential saliva biomarker for asthma severity Source: ERJ Open Res, 7 (3) 00984-2020; 10.1183/23120541.00984-2020 Year: 2021
Serum eosinophil cationic protein as a marker of disease severity in patients with bronchial asthma Source: Eur Respir J 2001; 18: Suppl. 33, 51s Year: 2001
Additional value of spirometry in risk assessment of acute respiratory disease in winter among patients with mild to moderate asthma or COPD Source: Eur Respir J 2002; 20: Suppl. 38, 473s Year: 2002
EBC periostin concentration in children with mild-to moderate asthma Source: International Congress 2019 – Asthma biomarkers, diagnostics and risk factors Year: 2019
Study on levels of high sensitivity C reactive protein in asthmatic patients during exacerbation and remission and its correlation with pulmonary function Source: Annual Congress 2007 - Mechanisms of airway inflammation Year: 2007
Effect of one moderate or mild exacerbation on lung function and serum inflammatory markers in ex smokers patients with COPD Source: Annual Congress 2009 - Cellular-tissue modifications and functional evaluation in COPD patients Year: 2009
Serum ECP levels do not correlate with degree of bronchial hyperresponsiveness in patients with cough variant asthma Source: Eur Respir J 2005; 26: Suppl. 49, 584s Year: 2005
Serum levels of IL-6 in adult patients with moderate to severe asthma. Source: International Congress 2017 – Novel mechanisms in asthma Year: 2017
Bronchial inflammation without asthma symptoms, relation to low neutrophil activity in serum Source: Eur Respir J 2002; 20: Suppl. 38, 143s Year: 2002
Cellular inflammatory pattern in induced sputum among patients with stable moderate or severe asthma Source: Annual Congress 2010 - Biomarkers and Diagnosis of asthma and allergic respiratory diseases Year: 2010
Baseline data and responses to oral steroid intervention in asthma and COPD: interim report from the BIOAIR EU study Source: Annual Congress 2007 - Asthma subphenotypes Year: 2007
Measuring inflammation inpaediatric severe asthma: biomarkers in clinical practice Source: Breathe, 16 (1) 190301; 10.1183/20734735.0301-2019 Year: 2020
Distribution of biomarkers in severe asthma and severe uncontrolled asthma Source: Virtual Congress 2021 – Pearls in asthma and respiratory burden research Year: 2021
Does eosinophil cationic protein (ECP) predict asthma outcome and response to treatment in asthmatic patients? Source: Annual Congress 2012 - Translational respiratory medicine in asthma and COPD Year: 2012
Omalizumab treatment reduces asthma exacerbations in children with moderate or severe persistent asthma Source: International Congress 2017 – Paediatric asthma: treatment modalities and behavioural issues Year: 2017
Sputum eosinophilia in the diagnosis and management of asthma of moderate severity in adults Source: Eur Respir J 2007; 30: Suppl. 51, 587s Year: 2007
Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study Source: Eur Respir J, 51 (5) 1702523; 10.1183/13993003.02523-2017 Year: 2018
Both moderate and severe exacerbations accelerate physical activity decline in COPD patients Source: Eur Respir J, 51 (1) 1702110; 10.1183/13993003.02110-2017 Year: 2018
Sputum eosinophil percentages during a moderate exacerbation of asthma and during a natural cold Source: Eur Respir J 2002; 20: Suppl. 38, 508s Year: 2002
Blood eosinophil in smokers and mild and moderate COPD patients Source: International Congress 2017 – Latest insights into the management of chronic lung diseases Year: 2017